Uncategorized
Eli Lilly and Company (LLY) Stock: Rises as Taltz and Zepbound Show Promising Results
TLDR Eli Lilly stock gains 0.62% as new Phase 3b findings highlight treatment gains. Combined therapy changes 482 proteins versus…
Latest stories tagged with this ticker.
TLDR Eli Lilly stock gains 0.62% as new Phase 3b findings highlight treatment gains. Combined therapy changes 482 proteins versus…